Market Trends of Intravenous Solutions Industry
The Total Parenteral Nutrition Segment is Expected to Witness Significant Growth Over the Forecast Period
The high burden of gynecological cancer worldwide is driving demand for total parenteral nutrition (TPN) to deliver essential nutrition, while rising development efforts by market players are expanding TPN offerings to meet this growing need. For instance, according to a report published in the Bulletin du Cancer Journal in August 2023, the increasing prevalence of malnutrition in cancer patients, coupled with the need for more personalized and adequate nutritional support, has created a significant demand. This shift has led to a rise in the application of total parenteral nutrition (TPN). Additionally, the proactive implementation of quality control measures and more consistent adherence to best practices have improved the relevance and effectiveness of TPN in oncology care. These advancements are expected to propel the growth of the total parenteral nutrition segment.
Furthermore, according to a report published by the World Health Organization in March 2024, 390 million were underweight. Globally, an estimated 149 million children under five experienced impaired growth, and 45 million faced severe undernutrition. The high burden of malnourishment is projected to boost the demand for total parenteral nutrition to treat malnutrition, accelerating segment growth during the forecast period.
The rising approvals of innovative parenteral nutrition solutions for every age group are also expected to propel the segment’s growth during the forecast period. For instance, in March 2022, Fresenius Kabi was granted an expanded indication for SMOFlipid Lipid Injectable Emulsion (ILE) for pediatric patients in the United States, including term and preterm neonates. The fluid was approved as one of the first four oil lipid emulsions for parenteral nutrition patients of every age. It can be used in the hospital for home care settings.
In conclusion, the growing prevalence of malnutrition, particularly in cancer patients, coupled with the increasing approval of innovative parenteral nutrition solutions, is expected to drive significant growth in the total parenteral nutrition segment.
North America is Expected to Hold a Significant Share in the Market Over the Forecast Period
North America is anticipated to capture a substantial market share due to the ongoing product launches and regulatory approvals, and rising prevalence of cancer. For instance, according to a report published by the American Cancer Society in January 2024, the estimated number of urinary system cancers in the United States is over 169,360. The region’s high burden of these diseases is expected to create demand for intravenous solutions during hospitalization or at home, further boosting the market growth during the forecast period.
Furthermore, the high utilization of saline in the region is also expected to propel the growth of the intravenous solution market. For instance, according to a report published in the Heliyon Journal in September 2023, the increasing utilization of 0.9% sodium chloride intravenous fluid (normal saline) for hydration purposes has significantly contributed to the rising demand in healthcare settings, with over 200 million liters administered annually in the United States. This widespread use and life-saving capabilities ensure its continued presence as a key intravenous solution in patient care. As a result, the growing consumption of saline directly drives the expansion of the North America intravenous solution market.
Additionally, growth strategies adopted by the market players in the region significantly contribute to the market's growth. For instance, in May 2022, Fresenius Kabi acquired Ivenix, Inc., to expand its infusion therapies and intravenous fluids offering in the United States. Moreover, in February 2022, B. Braun Medical received the US FDA approval to begin operations at its new IV saline solution manufacturing facility in Daytona Beach, Florida.
In conclusion, the North America intravenous solution market is poised for significant growth due to ongoing strategic expansions by key market players, and increased demand for saline.
